Novartis Casts Nets Globally To Snap Up Best Assets

The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.

Susanne Kreutz
Susanne Kreutz • Source: Novartis

Novartis AG‘s search for interesting early-stage assets is not confined to the usual US and European markets and the Swiss major’s collaboration with South Korea’s Chong Kun Dang Pharmaceutical Corp. inked earlier this week is a great example, according to Susanne Kreutz, head of corporate and business development.

The Basel-headquartered major has bagged exclusive global (excluding South Korea) development and commercialization rights to Chong Kun Dang’s Phase I...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By 

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By 

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.